| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | ENO3 |
| Uniprot No | P13929 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-434aa |
| 氨基酸序列 | MGSSHHHHHHSSGLVPRGSHMAMQKIFAREILDSRGNPTVEVDLHTAKGR FRAAVPSGASTGIYEALELRDGDKGRYLGKGVLKAVENINSTLGPALLQK KLSVADQEKVDKFMIELDGTENKSKFGANAILGVSLAVCKAGAAEKGVPL YRHIADLAGNPDLILPVPAFNVINGGSHAGNKLAMQEFMILPVGASSFKE AMRIGAEVYHHLKGVIKAKYGKDATNVGDEGGFAPNILENNEALELLKTA IQAAGYPDKVVIGMDVAASEFYRNGKYDLDFKSPDDPARHITGEKLGELY KSFIKNYPVVSIEDPFDQDDWATWTSFLSGVNIQIVGDDLTVTNPKRIAQ AVEKKACNCLLLKVNQIGSVTESIQACKLAQSNGWGVMVSHRSGETEDTF IADLVVGLCTGQIKTGAPCRSERLAKYNQLMRIEEALGDKAIFAGRKFRN PKAK |
| 预测分子量 | 49 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于ENO3重组蛋白的模拟参考文献示例(非真实文献，仅供格式参考)：
---
1. **《Expression and purification of recombinant human ENO3 for enzymatic characterization》**
*Zhang et al.*
该研究通过大肠杆菌系统表达并纯化了重组人ENO3蛋白，分析了其酶动力学特性，证实其在糖酵解中的催化活性依赖于Mg²⁺，并探讨了突变体对酶功能的影响。
2. **《ENO3 recombinant protein as a potential biomarker in muscle-related disorders》**
*Li et al.*
研究利用重组ENO3蛋白制备多克隆抗体，发现其在肌肉萎缩患者的血清中表达水平显著升高，提示其可能作为肌肉疾病的诊断标志物。
3. **《Structural insights into the interaction of ENO3 with cytoskeletal proteins》**
*Wang et al.*
通过X射线晶体学解析了重组ENO3的结构，揭示了其与肌动蛋白结合的特定结构域，为研究ENO3在肌肉细胞迁移中的作用提供了分子基础。
---
注：以上文献为示例，实际研究中请通过PubMed、Web of Science等平台检索真实文献。
ENO3. or beta-enolase, is a glycolytic enzyme encoded by the *ENO3* gene and primarily expressed in skeletal muscle. As a member of the enolase family, it catalyzes the conversion of 2-phosphoglycerate to phosphoenolpyruvate during glycolysis, playing a critical role in cellular energy metabolism. Unlike its isoforms (ENO1 and ENO2), ENO3 is muscle-specific, making it a key marker for studying muscle-related functions and disorders. Mutations in *ENO3* have been linked to metabolic myopathies, such as enolase deficiency, characterized by exercise intolerance and muscle weakness.
Recombinant ENO3 protein is produced using genetic engineering techniques, often by inserting the *ENO3* gene into expression systems like *E. coli* or mammalian cell lines. This allows large-scale production of the purified protein for research and therapeutic applications. Recombinant ENO3 retains enzymatic activity and structural integrity, enabling studies on its metabolic roles, interactions with other proteins, and potential involvement in non-glycolytic processes, including hypoxia adaptation and inflammatory responses.
In biomedical research, recombinant ENO3 is utilized to investigate muscle-specific pathologies, develop diagnostic assays, or explore its unexpected roles in diseases like cancer, where enolases may act as autoantigens or promote tumor progression. Its application extends to drug discovery, particularly in targeting metabolic pathways in muscle disorders or cancers. The protein’s stability and specificity also make it a candidate for biomarker development. Overall, recombinant ENO3 serves as a vital tool for unraveling muscle biology and advancing therapeutic strategies.
×
